Compare Bristol-Myers Squibb Co (BMY) vs Godaddy Inc (GDDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Godaddy Inc — how do they compare? Bristol-Myers Squibb Co trades at $63.65 (market cap $129.94B), while Godaddy Inc trades at $90.75 (market cap $11.49B). The key difference: Bristol-Myers Squibb Co is far larger — about 11.3× Godaddy Inc's market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while Godaddy Inc pays none. Which is the better fit depends on your goals.
| BMY | GDDY | |
|---|---|---|
Market Cap | $129.94B | $11.49B |
Sector | Health | Technology |
52-Week High | $65.89 | $148.88 |
52-Week Low | $42.60 | $75.07 |
Enterprise Value | $163.92B | $14.18B |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.
BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.
GoDaddy (GDDY) trades at $91.81, up 0.34% today, with a bearish technical signal but strong earnings beats in recent quarters. The company shows robust fundamentals with a 17.83% net income margin and a P/E of 13.48, indicating potential undervaluation. However, recent news highlights multiple securities investigations, creating investor uncertainty. Revenue growth is steady, projected at $5.1B for 2026, while cash flow trends improved in 2024 before a slight dip in 2025.
The stock presents a mixed outlook: analyst consensus is bullish with a $112.13 price target (21 buys, 15 holds, 1 sell), but technical indicators and legal risks weigh on near-term sentiment. Key opportunities include consistent earnings outperformance and solid profitability, while risks involve ongoing legal probes and high debt levels. Investors should balance fundamental strength against headline volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Godaddy Inc
GoDaddy is a provider of domain registration and aftermarket services, website hosting, security, design, and business productivity tools, commerce solutions, and domain registry services. The company primarily targets micro- to small businesses, website design professionals, registrar peers, and domain investors. Since acquiring payment processing platform Poynt in 2021, the company has expanded into omnicommerce solutions, including offering an online payment gateway and offline point-of-sale devices.
Read more on GDDY →
